AI Article Synopsis

  • RM, an aminosteroid developed by our research group, exhibits significant antitumor activity against nine cancer cell lines with minimal toxicity to normal cells.
  • In HL-60 leukemia cells, RM induces a G0/G1 cell cycle block and shows signs of apoptosis, evidenced by morphological changes captured through fluorescence microscopy.
  • The drug triggers a caspase-dependent death receptor pathway, as indicated by the cleavage of caspases-3 and -8, and PARP, while not affecting caspase-9.

Article Abstract

RM, a novel aminosteroid synthesized by our research group, shows a broad spectrum of antitumor activity against nine cancer cell lines and limited toxicity against two normal cell lines. However, its related mechanism of action has not yet been elucidated. In this study, we investigated the cellular and molecular events underlying the cytotoxicity of RM in human acute promyelocytic leukemia HL-60 cells. RM was found to induce a G0/G1 cell cycle block of HL-60 cells but not terminal myeloid differentiation. Interestingly, typical apoptotic morphological changes were exhibited by HL-60 cells treated with RM stained with Hoechst 33342 and examined by fluorescence microscopy. Apoptotic death assay using annexin-V/propidium iodide dual staining flow cytometry demonstrated a dose-dependent apoptotic effect of RM on HL-60 cells. In addition, RM induced the cleavage of caspase-3, caspase-8 and PARP, but not the cleavage of caspase-9. Our findings suggest that RM reduces HL-60 cells survival through a caspase-dependent death receptor pathway.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9548-6DOI Listing

Publication Analysis

Top Keywords

hl-60 cells
24
novel aminosteroid
8
cell cycle
8
promyelocytic leukemia
8
leukemia hl-60
8
cell lines
8
hl-60
6
cells
6
aminosteroid 5α-androstane-3α17β-diol
4
5α-androstane-3α17β-diol family
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!